KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to -$327.8 million.

  • Jazz Pharmaceuticals' Cash from Investing Activities fell 25311.53% to -$327.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 52457.79%. This contributed to the annual value of -$508.2 million for FY2024, which is 21165.75% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$327.8 million for Q3 2025, which was down 25311.53% from -$641.0 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Cash from Investing Activities high stood at $737.1 million for Q1 2021, and its period low was -$5.9 billion during Q2 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Cash from Investing Activities had a median value of -$89.2 million in 2022 and averaged -$393.0 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Cash from Investing Activities skyrocketed by 132691.74% in 2021, and later tumbled by 553882.21% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$10.1 million in 2021, then crashed by 3114.21% to -$324.4 million in 2022, then skyrocketed by 131.38% to $101.8 million in 2023, then crashed by 289.87% to -$193.3 million in 2024, then plummeted by 69.59% to -$327.8 million in 2025.
  • Its Cash from Investing Activities stands at -$327.8 million for Q3 2025, versus -$641.0 million for Q2 2025 and -$168.9 million for Q1 2025.